Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

被引：17
|
作者：
Malik, Sara [1 ]
Hassan, Shahzeb [1 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Istanbul Univ, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey
来源：
EXPERT REVIEW OF HEMATOLOGY | 2021年 / 14卷 / 11期
关键词：
Asciminib; chronic myeloid leukemia; flumatinib; HQP1351; K0706; novel therapies; olverembatinib; PF-114; tyrosine kinase inhibitor; vodobatinib; ASCIMINIB; THERAPY;
D O I：
10.1080/17474086.2021.1990034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：975 / 978
页数：4
相关论文
共 50 条
  • [1] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [2] Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Issa, Ghayas C.
    Jabbour, Elias
    Sasaki, Koji
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1714 - 1717
  • [3] PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    [J]. HAEMATOLOGICA, 2014, 99 : 336 - 336
  • [4] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [5] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
  • [6] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    [J]. LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [7] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
    Erbilgin, Yucel
    Eskazan, Ahmet Emre
    Ng, Ozden Hatirnaz
    Salihoglu, Ayse
    Elverdi, Tugrul
    Firtina, Sinem
    Tasar, Orcun
    Mercan, Sevcan
    Sisko, Sinem
    Khodzhaev, Khusan
    Ongoren, Seniz
    Ar, Muhlis Cem
    Baslar, Zafer
    Soysal, Teoman
    Sayitoglu, Muge
    Ozbek, Ugur
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
  • [8] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Press, Richard D.
    Kamel-Reid, Suzanne
    Ang, Daphne
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
  • [9] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Dakota Gustafson
    Jason E. Fish
    Jeffrey H. Lipton
    Nazanin Aghel
    [J]. Current Hematologic Malignancy Reports, 2020, 15 : 20 - 30
  • [10] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
12345